Brief: Galecto Publishes Results Showing Safety And Efficacy Of The Gb0139 Inhaled Galectin-3 Inhibitor In Hospitalized Covid-19 Patients On Standard Of Care

Damora Therapeutics

27/01/2022 12:53

Jan 27 (Reuters) - Galecto Inc  GLTO.O :
    * GALECTO PUBLISHES RESULTS SHOWING SAFETY AND EFFICACY OF
THE
GB0139 INHALED GALECTIN-3 INHIBITOR IN HOSPITALIZED COVID-19
PATIENTS ON STANDARD OF CARE
    * GALECTO INC - STUDY MET ITS PRIMARY ENDPOINT OF SAFETY AS
THERE
WERE NO OBSERVED TREATMENT-RELATED ADVERSE EVENTS
    * GALECTO INC - PLANS TO SEEK REGULATORY APPROVAL OF A
PROTOCOL
AMENDMENT TO REDUCE TARGET PATIENT POPULATION FOR GALACTIC-1
TRIAL

Source text for Eikon:  ID:nGNX5D4sXY 
Further company coverage:  GLTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))